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Abstract 
Background  
The design and use of convection-enhanced delivery catheters remains an active 
field as failed clinical trials have highlighted suboptimal distribution as a 
contributory factor to the failure of those studies. Recent studies indicate 
limitations and challenges in achieving target coverage using conventional point 
source delivery.  
New method 
The recessed step catheter(RSC), developed by this group, does not function as 
a point source delivery device, but instead utilises ‘controlled reflux’ of the 
infusate to a flow inhibiting recess feature. Here we investigate a range of 
clinically useful step lengths in agarose gel and investigate proof-of-principle in 
vivo(n=5). Infusion morphology was characterised in terms of length, width and 
distribution volume over a range of flow rates.  
Results 
Increases in catheter step length strongly correlated with increased infusion 
volume and length (r>0.90,p<0.001) while small but significant reductions of 
infusion width were recorded(r<-0.62,p<0.001). Step lengths below 6mm 
produced spherical infusion clouds while steps above 12mm produced elongated 
infusions. Increasing peak flow rates resulted in significant reductions in 
coverage at each step length, and increased risk of reflux beyond the step. 
Modifications to the infusion morphology using changes in step length were 
confirmed in vivo. 
Conclusions 
The RSC can be tailored to each patient’s unique anatomical requirements to 
maximise coverage and optimise distribution in targeted neurological structures. 
Loss mechanisms in vivo remain “real-world” challenges for all devices, but the 
combination of recess and variable catheter step length provide a simple 
mechanism for controlling the infusion morphology and maximising coverage for 
neurological indications.  
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Highlights  
• The recessed step catheter can be used to bypass the blood brain 
barrier in neurodegenerative or neuro-oncological indications to 
deliver therapeutics directly to target tissues 
• The variable step length can be used to control the infusion 
morphology in convection-enhanced delivery infusions to match 
target structures 
• Novel surgical trajectories could be employed to maximise coverage 
of neuroanatomical targets such as the striatum, thalamus or pons  
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1 Introduction 
Systemic routes of administration for macromolecules targeting neurological 
conditions have significant limitations for achieving therapeutic drug 
concentrations within the central nervous system (CNS). Transportation from the 
blood stream to neurological tissues is severely limited because of the blood 
brain barrier (Stockwell et al. 2013). Direct delivery via a series of intracranially 
implanted catheters offers a promising alternative to this route as expensive or 
toxic substances can be administered at much lower doses than would be 
required systemically to achieve the same local concentration. It also allows 
drugs to be delivered to specific targeted tissues, and not widespread 
throughout the CNS.  
Convection-Enhanced Delivery (CED) is an infusion methodology which utilises 
implanted catheters to increase local hydrostatic pressures at the site of infusion 
to mimic vasogenic oedema (Bobo et al. 1994). Infusion concentrations are 
elevated above that which could be achieved via diffusion alone, as the random 
path of diffusive molecules would take days/weeks to reach a similar distance 
from the site of infusion (Saltzman 2001). 
Despite initial description of the technique being published in 1994 no clinically 
available treatment utilising CED is currently available outside of investigational 
clinical trials, indicating the difficulty of translation from lab and pre-clinical trials 
into the clinic (Gill et al. 2003; Lang et al. 2006; Kunwar et al. 2010; Mueller et 
al. 2011; Warren Olanow et al. 2015).  
While higher than average placebo responses are a known phenomenon in 
neurological studies (Goetz et al. 2008; Kunwar et al. 2010), cited among the 
reasons for failure of these studies was the requirement for increased experience 
of the users, improved equipment and predictability of implanted devices. 
The incorporation of distribution predictions within the planning stage of 
neurosurgical procedures has been advocated and will no doubt provide a step 
change towards improved trial outcomes (Raghavan et al. 2016). Underpinning 
such algorithms however must be an empirical knowledge of how each device 
performs. While not the only devices used for direct delivery, End Port Catheters 
(EPC) are often described as having an idealised, spherical distribution pattern 
which emanates from their tips (Ivanchenko et al. 2010). Investigations using 
devices with this aim have shown that this use is suboptimal in that multiple 
payloads are often required to deliver clinically meaningful infusion volumes 
(Bartus et al. 2013; Sillay et al. 2013). This increases the duration of the 
infusions but also the complexity of the implant as the device must be moved 
multiple times throughout a treatment. Further, anatomical structures of interest 
for some neurodegenerative pathologies, such as the putamen and caudate 
nucleus are themselves, not spherical but elongate. Despite axial trajectories for 
foetal cell deposition being described in 1995 (Breeze et al. 1995), implantation 
(Brady et al. 2013; Bankiewicz et al. 2016) likely due to the surgical and 
anaesthetic challenges of implantation and extended infusions associated with 
keeping patients in the prone position to access the long axis of targets such as 
the caudate nucleus or the putamen. 
We developed a fully polymeric catheter device which utilises image guided, 
robot assisted implantation remote from an MRI suite (Barua et al. 2013a; Gill et 
al. 2013; Lewis 2015) enabling implantation along almost any desired trajectory. 
Once implanted, real time scans are possible to track and optimise the infusion 
regimes. The recessed step catheter does not function as a point source 
distribution device but one that utilises a form of “controlled reflux” (Woolley et 
al. 2013; Singleton et al. 2017). As the recess forms an inhibiting feature, fluid 
flows from the tip of the device around the boundary to the recess (along the 
catheter to the outer guide tube, defining the step length – see Figure 1 ), 
providing a potential mechanism for higher overall coverage in target structures 
within a single implantation procedure. The use and optimisation of chronically 
implanted catheters are however little known and further research is required for 
optimisation (Lewis et al. 2016). Here we investigate and characterise the 
variable step length feature of the recessed step catheter to optimise the 
morphology of infusions as a means of maximising coverage of neuro-anatomical 
structures. 
2 Materials and Methods 
2.1 In vitro evaluation 
2.1.1 Agarose gel and infusate preparation 
Agarose gel (0.6%) was prepared by mixing molecular grade agarose gel 
(Severn Biotech LTD, UK) with concentrated Tris Borate-ETDA buffer (Severn 
Biotech, UK) and deionised water. The mixture was heated in a microwave for 
5minutes, stirred and then heated further until all powder had fully dissolved. 
The heated solution was decanted into 50x50x150 clear, rectangular acrylic 
containers (Volume:375ml) and left to cool and solidify to room temperature.  
A 3mm acrylic lid was secured to the pot and used to simulate the skull, allowing 
the recessed step catheter to be press fit into the acrylic plate, mimicking the 
implantation procedure. 
Trypan Blue powder (Sigma Aldrich®) was weighted and dissolved in deionised 
water to a concentration of 0.4% and used as a high visual contrast infusate.  
2.1.2 Catheter 
Recessed Step Catheters (neuro|infuseTM, Renishaw PLC, UK) are formed in 
three parts using an Outer Guide Tube (OGT), Inner Guide Tube (IGT) and a 
sub-millimetre diameter catheter (Gill et al. 2013; Lewis 2015). The device was 
prepared by cutting an OGT to 60mm and the IGT to 58.5mm creating a 1.5mm 
recess. Catheters were cut at lengths of 63, 66, 72, 78mm, creating step lengths 
of 3, 6, 12 and 18mm beyond the OGT.  
 
Figure 1; Fully implantable recessed step catheter assembly, inset showing a cut away view of the 
tubing and the formation of the recess 
2.1.3 Delivery tooling 
As a polymeric device, each of the guide tube elements must be delivered over 
delivery rods to ensure they maintain target accuracy. The OGT is delivered over 
a tungsten carbide delivery rod and held just short of the final implantation 
position. The OGT is then advanced over the rod to create a tissue/ gel plug in 
the base of the assembly. The IGT is then passed over a steel rod while 
aspiration is used to minimise the introduction of air into the infusion area.  
A 0.6mm diameter rod, is then used to penetrate the gel beyond the OGT to the 
depth of the catheter, creating a track for the unsupported catheter to maintain 
target accuracy. 
2.1.4 Test set up 
Agarose pots were held in a bespoke fixation rig (Figure 2). A human 
stereotactic frame (Radionics® CRWTM, Integra Lifesciences Corp.) was used to 
aid delivery of guide rods and catheter elements into the gel. A DSLR camera 
(Model 1200D, Canon Inc) was attached to a laptop fitted with Digital Photo 
Professional (Canon, Inc) remote shooting software. Additional lighting was used 
as required to illuminate the infusion. B|BraunTM Perfusor Space syringe pumps 
were used to run ramp and taper infusion regimes (Figure 3).  
  
  
 
Figure 2; Schematic of gel infusion test set up 
2.1.5 Infusion volume and regime 
A retrospective study of anonymised surgical plans from a backlist of some of 
the authors historical Deep Brain Stimulation (DBS) cases was performed to 
establish baseline volumes of two likely neurodegenerative target structures, the 
putamen and caudate nucleus. 143 Parkinson’s disease patients were analysed 
using an auto-segmentation tool (within Renishaw’s neuroinspireTM surgical 
planning software) for anatomical structures  
Average putamen volumes were 4.30±0.03ml (range: 2.89-5.94ml) which 
compares favourably to a smaller study conducted using only 11 cases (Yin et al. 
2009) 
Average caudate nucleus volumes were 2.90± 0.03ml (range 2.03-4.64ml) 
which was similar to previously published data from the same source. 
Interstitial space in grey matter accounts for ~20% of the volume fraction 
(Roitbak and Sykova 1999), published values for infusions into the rat striatum 
confirm a Vd/Vi ratio of 5±0.2 (mean ± standard deviation)(Chen et al. 1999).  
Targeting complete coverage of the average putamen would therefore require an 
infusion volume of at least 0.8ml (800µl), or 0.4ml (400µl) split over 2 
catheters.  
Slowly increasing the interstitial pressure at the target site by stepping or 
ramping the infusion rate from low to high minimises the risk of overwhelming 
inhibition features such as a step or recesses (Bankiewicz et al. 2000; 
Bienemann et al. 2012; Barua et al. 2013b; Gill et al. 2013).  
Syringe pumps (Perfusor® Space, B|Braun) were programmed with three linear 
ramp and taper profiles delivering a fixed infusion volume of 400µl, ramping 
from zero to the peak flow rate (Q) over 40mins (Figure 3). Total infusion times 
were 1hr (Q=0.6ml/hr[10µl/min]), 1hr40mins (Q=0.3ml/hr[5µl/min]) and 
4hrs21mins (Q=0.1ml/hr[1.3µl/min]) which were all considered clinically 
translatable.  
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A minimum of 9 repeats for each step length at each flow rate were performed 
(n=108). 
 
Figure 3; Investigational, clinically translatable infusion regimes for intermittent delivery 
2.1.6 Infusion image acquisition rig 
Following completion of the infusion (<10mins) the agarose gels were emptied 
into a bespoke cutting matrix. 150mm long skin grafting blades (Swann Morton) 
were used to section the gel into 3mm slices. Slices containing the midline of the 
infusion cloud were laid onto a graduated platform (Figure 4). Compressive 
distortions were minimised as the gel was smoothed to the known cross-
sectional dimensions. A diffusion light box was placed over the rig prior to image 
acquisition with a Canon camera (described above) to provide uniform and 
consistent lighting of the samples. 
Images of the infused gel were recorded within approximately 10minutes 
following completion of the infusion to minimise diffusion effects.  
 
Figure 4; infusion imaging rig showing well demarcated infusion clouds within 3mm thick slices of 
agarose gel against a graduated border 
2.1.7 Image analysis 
Images were loaded into the image segmentation toolbox of Matlab 9.2 (The 
Mathworks, Inc., Natick, Massachusetts, United States). Infusion areas were 
magnified to fill the screen and the manual polygon plotter tool used to profile 
the boundary of the infusion, creating a segmented binary image with the same 
dimensions as the base image. The binary image was exported to the 
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workspace. Pixel width was calibrated for each image using the inbuilt steel rules 
which formed part of the imaging rig. Infusion Distribution Volume (Vd) was 
calculated on a pixel line basis as a cylindrical volume; Infusion width was 
halved, creating a radius while the height was the calibrated pixel height. 
Calculations were repeated for each line and the sum total provided the Vd. 
Maximum infusion length and width were also recorded.  
Sectioned gel slices displayed a clear profile boundary for the infusions as a 
dark, saturated core with a weaker, diffuse boundary. The band of diffuse 
infusate was routinely 1-2mm in width and inherently variable, to minimise 
subjectivity, the manual profiles were created for each infusion at the border of 
the highly saturated core region. Analysed volumes are therefore likely to 
underestimate total coverage but provide a more direct comparison between 
tests.  
2.2 In vivo evaluation 
2.2.1 Surgical procedures  
Surgical procedures were performed in accordance with the Animals (Scientific 
Procedures) Act (1986) under specific UK Home Office project and personal 
licence (project licence number 30/2909) at a licensed establishment. Study 
protocols were pre-approved by the University of Bristol Ethical Review board. 
Bilateral infusions into the grey matter (putamen or thalamus) of 5 large white 
landrace pigs were conducted using the recessed step catheter (n=12 infusions).  
Outer guide tubes were placed within the boundary of the target structure and 
the catheter tip was implanted to sufficient depth to create a series of increasing 
step lengths to a maximum of 12mm (restricted by the size of the thalamus in 
the porcine model).  
Anaesthesia, head fixation, MRI scanning and stereotactic procedures were 
performed as previously described (White et al. 2011; Barua et al. 2013c).   
2.2.2 Test infusions 
Artificial cerebrospinal fluid (aCSF) was prepared with a 2mM concentration of 
gadolinium based contrast agent (GBCA), MagnevistTM (Bayer) and loaded into a 
fixed volume reservoir. Infusion volumes to the putamen were typically 120µl 
while infusions into the larger thalamus were typically 200µl. 
Real time (sequential T1 weighted) MRI scans were performed by placing the 
fixed volume reservoirs downstream of 6m access lines which could extend into 
the bore of the scanner, allowing the infusion pumps to remain in the control 
room. Ramped infusion regimes were used as described above with flow rates 
peaking at 0.18-0.3ml/hr. 
2.3 Statistical analysis 
Sample groups larger than 2 were analysed using a one-way ANOVA to establish 
statistically significant differences in mean populations of Vd, infusion width and 
length between flow rates and between step lengths.  
Pearson correlation coefficients were calculated for the distribution volume, 
width and length at each infusion flow rate over the step length groups (Field 
2007).  
3 Results  
3.1 In vitro infusion morphology: Infusion length and width 
In the gel model, as expected, there was a very strong correlation between 
increased step length (SL) and increased infusion length (Figure 5a: Q1[r=0.95, 
p<0.001], Q5[r= 0.98, p<0.001], Q10[r=0.98, p<0.001]) as infusions refluxed 
to the flow inhibiting feature. Increasing the infusion length also resulted in a 
numerically small but significant drop in the maximum infusion width at each 
step length (Figure 5b: Q1[r=-0.89, p<0.001], Q5[r=-0.83, p<0.001], Q10[r=-
0.60, p<0.001]).  
Average distribution lengths were significantly reduced when increasing the 
infusion flow rate (Q) at each of the step lengths investigated (SL(3mm); 
F(2,27)=31.6, p<0.001, SL(6mm); F(2,29)=25.3, p<0.001, SL(12mm); 
F(2,30)=19.7, p<0.001, SL(18mm); F(2,29)=9.5, p<0.001). Average 
distribution width was also significantly reduced when increasing the infusion 
flow rate (Q) at each of the step lengths investigated (SL(3mm); F(2,27)=116.0, 
p<0.001, SL(6mm); F(2,29)=49.9, p<0.001, SL(12mm); F(2,30)=75.2, 
p<0.001, SL(18mm); F(2,29)=46.8, p<0.001). 
 
 
b 
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Figure 5; a) Q1 (top), Q5 (middle) and Q10 (bottom) trendlines for distribution length versus step length, 
b) Q1 (top), Q5 (middle) and Q10 (bottom) trendlines for distribution width versus step length 
3.2 In vitro infusion morphology: Distribution volume 
Increasing the RSC step length resulted in a significant increase in the volume 
covered across all infusion flow rates tested (Q1[r=0.66, p<0.001], Q5[r=0.74, 
p<0.001], Q10[r=0.78, p<0.001]). Average distribution volumes were analysed 
immediately after the completion of the infusion. Vd was significantly reduced 
when the infusion flow rate (Q) at each step length was increased (SL(3mm); 
F(2,27)= 71.3, p<0.001, SL(6mm); F(2,29)= 65.4, p<0.001, SL(12mm); 
F(2,30)= 103.6, p<0.001, SL(18mm); F(2,29)= 69.4, p<0.001) (Figure 6). 
 
 
Figure 6; Q1 (top), Q5 (middle) and Q10 (bottom) trendlines for distribution volumes versus step 
length 
3.3 In vivo infusion morphology: Length and width 
In vivo infusions were grouped into two volumes; 120µl for the putamen and 
200µl for the thalamus. Infusions into the porcine grey matter show a strong 
correlation for a linear rise of infusion length as the catheter step length is 
increased (Vi(120µl):R=0.90, p=0.006, Vi(200µl):R=0.84, p=0.03) (Figure 7a). 
While the infusion widths reduce in both infusion volumes, the magnitude of the 
change is non-significant in the putamen (Vi(120µl):R=-0.62, p=0.13, 
Vi(200µl):R=-0.82, p=0.05)(Figure 7b). 
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Figure 7; a) Length of infusions achieved in the porcine grey matter; triangles=120µl (at 5µl/min), 
circles = 200µl (at 3µl/min); b) width of infusions achieved in the porcine white matter; 
triangles=120µl (at 5µl/min), circles = 200µl (at 3µl/min) 
As the 120µl infusions reached a slightly higher peak flow rate of 0.3ml/hr, a 
shorter infusion length and smaller width may be anticipated in line with the 
results of the gel experiments. All infusions refluxed back to the inhibiting step in 
a predicable fashion across all lengths tested (3-12mm) (Figure 8a-d).  
3.4 In vivo infusion morphology: distribution  
All infusions showed small numerical increases in coverage as the step length 
increased, but failed to show significance (Vi(120µl):R=0.77, p=0.27, 
Vi(200µl):R=0.77, p=0.07) (Figure 8e).  
 
Figure 8; in vivo MRI scans of infusions using the recessed step catheter in the porcine model - a) 
5mmstep, b) 6mm step, c) 8mm step, d) 12mm step, e) distribution volume achieved from 
infusions into the porcine grey matter; triangles=120µl (at 0.3ml/hr) circles = 200µl (at 
0.18ml/hr)  
4 Discussion 
4.1 Controlled reflux 
The catheter was implanted under a pressure head, provided by the infusion 
pump to minimise the inclusion of tissue/ gel into the distal tip of the catheter. 
Infusions were run using a stepped or ramped profile to minimise the pressure 
local to the catheter tip upon initial release of the internal line pressure. The 
initial reflux was instantaneous, passing from the tip of the catheter immediately 
to the recessed step (Figure 9b). Once flow was retarded below the step, a 
stable pressure region is believed to establish and fluid flow pathways were 
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initiated radially along the step region (Figure 9c-e). Convection continued until 
a critical point is reached where local pressures required to continue infusions 
radially from the step, exceed those provided by the flow inhibitor and secondary 
reflux commences around the outer guide tube (Figure 9f).  
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Figure 9; The stages of controlled reflux; a) implanted device – SL=Step Length, b) initial reflux, 
c) ramped/ stepped increase in the flow rate leading to containment of flow front at the inhibition 
feature and establishment of lateral flow pathways, d) peak flow rate achieved and stable 
convection reached, e) optimal limit of delivery, f) overload – pressure exceeds inhibition feature 
limit 
4.2 Controlling infusion morphology 
The increase of backflow with increases in catheter diameter and infusion flow 
rate are by now, well-known phenomena (Chen et al. 1999). Controlled reflux 
(Woolley et al. 2013) is therefore attained by embracing this inevitable event 
and restricting it below a flow inhibiting feature (Figure 1 and Figure 9). The first 
evidence of a recessed step was previously described by this group (Gill et al. 
2013). Unlike monolithic alternatives however, the recessed step catheter can be 
cut and assembled based on patient data giving a fully analogue step length. 
Here we investigated the modification of the step length beyond the previously 
utilised standard of 3mm (Krauze et al. 2005; Gill et al. 2013). This investigation 
in the gel model has identified the predictable behaviour of the RSC to create 
infusions with increasing lengths in a robust way, utilising controlled reflux 
(Figure 10a-b) which could be used to maximise coverage of pre-clinical or 
human neurological structures.  
 Figure 10; a) Schematic of infusion morphology characteristics associated with increasing the step 
length of the recessed step catheter, b) actual infusions associated with increasing step lengths 
Unlike point source delivery devices, the RSC infusion cloud length closely 
matches that of the step length. Conversely and logically, the longer infusion 
clouds which share a fixed input volume, narrowed as a consequence, limiting 
lateral coverage which is typical of point source CED infusions. Less obvious was 
the reduction in coverage volumes which resulted from infusions into short step 
length assemblies. With an infusion volume (Vi) of 400µl for each experiment, a 
distribution volume (Vd) between 1600-2000µl may have been anticipated given 
a Vd/Vi ratio of 4:1-5:1. The mean infusion volumes recorded here range from 
550-1700µl. As spherical infusions must convect to a larger radial distance than 
infusions spread over the region of a longer step length, spherical infusions must 
have higher concentration cores at the end of an infusion.  
These characteristic profiles identified in the gels were also observed in vivo, 
with infusate refluxing in a controlled manner to the step before stabilising and 
distributing laterally. As might be expected, infusions into live tissues are less 
uniform than in homogenous gels however linear increases in infusion cloud 
length and a reduction in width were observed across the small number of 
catheters tested which demonstrates proof of principle.  
We observed that secondary reflux occurred most often in tests utilising short 
step lengths (3-6mm) and the highest flow rate (0.6ml/hr). This may help 
explain the difficulty in directly translating pre-clinical results to clinic, as smaller 
infusion volumes would typically be infused to cope with the smaller anatomy of, 
for example, rodent, porcine and primate models, resulting in less reflux. 
Generally, faster flow rates are regarded as more desirable in human 
applications as shorter infusions are more cost effective and preferred by both 
clinicians and patients (Bankiewicz et al. 2016). It is of interest to note therefore 
that the trends observed in this study indicate that faster rates are associated 
with smaller distributions at the end of the infusion and increased rates of 
a 
b 
undesirable reflux. It is noteworthy that the infusion duration at 0.1ml/hr takes 
more than 3hrs longer than at 0.6ml/hr providing more time for fluid pathways 
to develop in the substrate. High concentration gradients will of course continue 
to distribute after the end of the infusion, but through the action of residual 
pressure and diffusion alone. In vivo, such action would be subject to loss 
mechanisms (e.g. metabolism, drug half-life, perivascular losses and 
cerebrospinal fluid turnover). High concentration, homogenous coverage of a 
large area is therefore of primary interest. A compromise must therefore be 
struck between the preferred, short infusion times resulting in smaller 
distribution volumes, or longer infusion times that provide greater coverage, 
reduced risk of reflux but greater risk of unavoidable losses via natural clearance 
mechanisms. 
As previously discussed, maximising coverage of target structures can be better 
achieved if the infusion morphology more closely matches that of the target. 
Dividing the length to the width of each infusion respectively, normalises the 
distribution morphology in to two distinct types; Spherical and Cylindrical. 
 
Figure 11; Infusion morphology aspect ratio 
The shorter step lengths, 3 and 6mm, produce a spherical like infusion with a 
length/width ratio of 1:1 to 1:1.5 (for comparable, clinically relevant infusion 
volumes), which would account for the point source distributions historically 
expected from CED devices. Increasing the step length above 12mm resulted in 
infusion aspect ratios of 2:1 or 3:1 (Figure 11).  
Application of the RSC characteristics to clinical indications would see safe 
trajectories being chosen based on maximising the catheter step length within 
the target structure, providing patient specific opportunities to maximise target 
coverage. While in vivo loss pathways, clearing mechanisms and reflux remain 
real world challenges, this basic empirical model of infusion morphologies can 
provide a useful tool when planning catheter implantation targets and 
trajectories.   
Spherical infusions may continue to suit targets such as the pons or thalamus 
while elongate, cylindrical infusions would match structures like the putamen, 
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caudate nucleus or hippocampus (etc.). This may be over simplistic however, as 
the target tissue volume is not homogeneously distributed throughout structures 
like the putamen. The anterior aspect of the putamen is wider and taller than in 
the posterior of the structure. Preferential surgical planning strategies may 
combine the placement of a shorter stepped catheter vertically, down into the 
anterior portion while further catheters with much longer steps could be placed 
along the long, midline axis of the structure, from an anterior or posterior 
approach (e.g. Figure 12).   
 
Figure 12; Example a drug delivery surgical plan within neuro|inspireTM (Renishaw plc, UK) that 
may maximise structure coverage  
4.3 Intervening in refluxing infusions 
As described above, we observed secondary reflux at the highest frequency in 
experiments with short step lengths and high flow rates. Once a reflux pathway 
has developed large volumes are continually lost down this path of least 
resistance.  
As an additional investigational endpoint, we investigated the ability of the user 
to halt reflux as it became visible in the gel model. Twelve infusions were 
performed using 3, 6 and 12mm steps with infusions ramped to the fastest flow 
rate (0.6ml/hr) in 40mins. Secondary reflux occurred routinely within the first 
30mins after initiating the infusion (Figure 13 a-f), which may account in part for 
the lower distributions seen. Once observed, the user intervened in the infusion 
regime, dropping the infusion rate to 0.1ml/hr or initiating a new ramp profile to 
0.1ml/hr. In both cases the secondary reflux was halted at the initially observed 
level and the remaining infusion volume continued to develop as desired below 
the recessed step (Figure 13 g-l).  
 
 
Figure 13; Progression of infusions: a-f) standard 40minute ramp run to peak rate of 0.6ml/hr 
(arrow indicates initiation of visible secondary reflux), g-l) standard 40minute ramp run to peak 
rate of 0.6ml/hr halted and dropped to lower rate after visible reflux begins  
Our preliminary investigations suggest that priming the flow pathways ahead of 
increasing flow rates may yield favourable outcomes but further work is required 
to optimise this paradigm. As there is inherent variability within 
neurodegenerative populations our investigations would discourage the use of a 
“one size fits all” approach, and real time or post-infusion imaging would 
augment a treatment regime which enables the clinician to “drive” the implanted 
system based on real feedback. Implanted catheters could then be optimised 
with initial infusion parameters, but fully implanted MRI compatible systems also 
offer the ability to maintain long term performance through periodic test 
infusions.  
5 Conclusions 
We have demonstrated how the recessed step catheter can be used to control 
the morphology of infusates within an idealised, homogeneous gel model and 
demonstrated proof of this principle in vivo in porcine grey matter structures. 
The drive towards ever faster flow rates to minimise clinical time must be 
balanced against the increased risk of losses due to reflux and reduced 
distribution volumes. Further work is required to investigate optimal infusion 
regimes for minimising reflux.  
a          b             c                d              e             f 
g        h             i             j             k                 l 
Real time or post-infusion imaging offers users the opportunity to fine tune 
infusion regimes, as we have demonstrated that reducing infusion rates can offer 
improved distribution volumes and an opportunity to actively control infusion 
morphology. Real time or post infusion imaging therefore remains critical to CED 
treatments in order to optimise distributions in an inherently variable patient 
population. A fully MRI compatible implant will enable periodic infusion 
modulation to maximise coverage in the desired target anatomy over time or 
optimise catheters placed in unavoidable, leakage pathway areas of the 
parenchyma.  
Further work is required to understand how these observations may be 
translated to acute and chronic infusions in the human diseased brain. The 
challenge to clinicians utilising CED systems remains the integration of current 
knowledge of surgical planning techniques and the integration of expensive real-
time imaging for the benefit of long term optimisation of target coverage. 
Continued investment in CED platforms is resulting in more robust designs being 
available for investigational and clinical trial use. Continued research to optimise 
acute and chronic CED devices, as well as their infusion regimes, is necessary to 
maximise the coverage of neuroanatomical structures and provide the best 
chance of success in neurodegenerative and neuro-oncological treatments and 
investigational studies. Development and use of similar devices pre-clinically and 
clinically is essential to translate the learning and experiences gained. 
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